Please login to the form below

Not currently logged in
Email:
Password:

ThromoboGenics appoints Thomas Clay as chairman of the board

He moves from his previous position as non-executive director

Thomas ClayBelgium-based biotech ThromboGenics has appointed non-executive director Thomas Clay as its new chairman of the board and succeeds Staf Van Reet, who retires.

Clay has been a non-executive director of ThromboGenics since 2011 when he replaced his father, Landon Clay.

He said: “I Am very honoured to be appointed as chairman of the board of ThromboGenics at a time when the company is starting to make excellent progress with its exciting pipeline of four novel therapies for treating diabetic eye disease.”

Clay is also vice-president of East Hill Management, a US-based investment company and serves as chairman and CEO of Golden Queen Mining and as a director of the Clay Mathematics Institute.

Patrik De Haes, chief executive officer of ThromboGenics, said: “I am delighted that Thomas has agreed to take on the role of chairman, his rich experience and deep understanding of ThromboGenics and life sciences in general will be invaluable for the company in achieving its objectives going forward.”

27th June 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...